Witnessing the stock’s movement on the chart, on Thursday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) set off with pace as it heaved 1.24% to $370.0, before settling in for the price of $365.46 at the close. Taking a more long-term approach, ALNY posted a 52-week range of $205.87-$495.55.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 23.11%. Meanwhile, its Annual Earning per share during the time was 23.11%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 214.99%. This publicly-traded company’s shares outstanding now amounts to $131.79 million, simultaneously with a float of $129.77 million. The organization now has a market capitalization sitting at $48.88 billion.
Alnylam Pharmaceuticals Inc (ALNY) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Alnylam Pharmaceuticals Inc’s current insider ownership accounts for 1.77%, in contrast to 99.50% institutional ownership. According to the most recent insider trade that took place on Jan 12 ’26, this organization’s EVP Chief R&D sold 1,510 shares at the rate of 362.87, making the entire transaction reach 547,929 in total value, affecting insider ownership by 22,511. Preceding that transaction, on Jan 12 ’26, Company’s Chief Executive Officer sold 9,577 for 362.86, making the whole transaction’s value amount to 3,475,157. This particular insider is now the holder of 78,411 in total.
Alnylam Pharmaceuticals Inc (ALNY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.34 per share during the current fiscal year. Alnylam Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 214.99% and is forecasted to reach 7.69 in the upcoming year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Let’s observe the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). It’s Quick Ratio in the last reported quarter now stands at 2.49. Alongside those numbers, its PE Ratio stands at $1539.10, and its Beta score is 0.36. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 15.23. Similarly, its price to free cash flow for trailing twelve months is now 220.83.
In the same vein, ALNY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.24, a figure that is expected to reach 1.20 in the next quarter, and analysts are predicting that it will be 7.69 at the market close of one year from today.
